Table 3.
Prognostic factors of OS
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | aHR | 95% CI | p-value | |
| Age > 60 yr | 0.78 | 0.57–1.07 | 0.125 | |||
| Male | 1.04 | 0.63–1.72 | 0.886 | |||
| PIVKA II > 250 mAU/mL | 1.77 | 1.27–2.46 | 0.001 | |||
| AFP > 200 ng/mL | 2.11 | 1.54–2.89 | < 0.001 | 1.73 | 1.23–2.45 | 0.002 |
| Total bilirubin | 1.20 | 1.11–1.29 | < 0.001 | 1.18 | 1.09–1.29 | < 0.001 |
| Albumin | 0.62 | 0.47–0.82 | 0.001 | |||
| ALT | 1.01 | 1.00–1.01 | 0.003 | 1.00 | 1.00–1.01 | 0.039 |
| AST | 1.00 | 1.00–1.01 | < 0.001 | |||
| PT | 2.29 | 1.40–3.74 | 0.001 | |||
| Presence of ascites | 1.97 | 1.41–2.77 | < 0.001 | |||
| ECOG 1 (vs 0) | 2.09 | 1.50–2.90 | < 0.001 | 1.98 | 1.41–2.77 | < 0.001 |
| Child B, C (vs A) | 1.88 | 1.32–2.66 | < 0.001 | |||
| BCLC stage C, D (vs B) | 1.72 | 1.03–2.89 | 0.039 | 1.77 | 1.01–3.10 | 0.045 |
| Tumor size | 1.01 | 1.01–1.01 | < 0.001 | 1.01 | 1.00–1.01 | < 0.001 |
| Extrahepatic metastasis | 0.96 | 0.69–1.33 | 0.809 | |||
| Portal vein thrombosis | 1.53 | 1.13–2.09 | 0.007 | |||
| Biliary invasion | 1.44 | 0.80–2.60 | 0.223 | |||
| Lenvatinib (vs sorafenib) | 1.41 | 0.96–2.08 | 0.077 | 1.36 | 0.89–2.07 | 0.154 |
| Previous anti-HCC treatment | 0.46 | 0.31–0.68 | < 0.001 | |||
Multivariable analysis was performed using variables with p value under 0.05 at univariable analysis
HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval; PIVKA, protein induced by vitamin K absence or antagonists-II; AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer